Publication Instructions:

BMT CTN Protocol 0401
- Primary and Ancillary Studies –

The requirements below are for publications and presentations made pursuant to the primary BMT CTN Study 0401. For ancillary studies, please contact the e-mail below.

Acknowledgment Requirements:

For all Publications, Reports, Presentations, Symposiums, etc.

"Support for this study was provided by grant #U10HL069294 to the Blood and Marrow Transplant Clinical Trials Network from the National Heart, Lung, and Blood Institute and the National Cancer Institute, and SWOG, along with contributions by GlaxoSmithKline. The content is solely the responsibility of the authors and does not necessarily represent the official views of the above mentioned parties."

For correlative studies utilizing biospecimens and/or clinical data obtained from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center, include the following as applicable:

If the Research Plan involves collaboration with Study Investigators, acknowledge the source of the data by including language similar to the following either in the acknowledgement or in the text of the manuscript:

"This manuscript was prepared using BMT CTN 0401 Research Materials obtained from the NHLBI."

If the Research Plan does not involve collaboration with Study investigators, or if the Study has ended, use the following language:

"This manuscript was prepared using BMT CTN 0401 Research Materials obtained from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center and does not necessarily reflect the opinions or views of the BMT CTN 0401 or the NHLBI."

Manuscripts and abstracts resulting from the Research Plan should not use the name of the Study in the title of the manuscript/abstract unless the title clearly denotes the source of the Research Materials as being from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center.

The following language should be inserted in the acknowledgements for all BMT CTN Studies that utilize CIBMTR data:
The CIBMTR registry is supported primarily by the U24-CA76518 from the National Cancer Institute, the National Heart, Lung, and Blood Institute, and the National Institute of Allergy and Infectious Diseases and from HHSH234200637015C (HRSA/DHHS) to the Center for International Blood and Marrow Transplant Research.

Review Requirements:

For all Publications, Reports, Presentations, Symposiums, etc.

BMT CTN: Abstracts, presentations, and proposed publications relating to data obtained from BMT CTN protocols or to activities of BMT CTN Committees or Protocol Teams are to be submitted to the DCC for review.

GlaxoSmithKline: A copy of all draft publications and presentations are to be submitted to GSK prior to submission for publication or presentation. GSK will have up to **30 consecutive days** to review information, submit questions, and provide comments with the express understanding that all decisions regarding publication will be at the sole discretion of the investigators, unless GSK's objections relate to information provided by GSK as confidential prior to commencing the research project, in which case, such information shall be removed from the publication or presentation.

SWOG needs to review publications prior to release.

Questions regarding the above requirements may be directed to the Data Coordinating Center, NMDP Contracts & Procurement Department at NMDP_BMTCTN_Pub@nmdp.org.